Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials
CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. The decision to stop the trials is based on results of a futility analysis conducted by an independent data monitoring committee, which indicated the trials were unlikely to meet their primary endpoint upon completion. The recommendation to stop the studies was not based on safety concerns.
“This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience. We are incredibly grateful to all the Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly to this research,” said Michel Vounatsos, Chief Executive Officer at Biogen. “Biogen’s history has been based on pioneering innovation, learning from successes and setbacks. Driven by our steadfast commitment to patients and our strong business foundation, we will continue advancing our pipeline of potential therapies in Alzheimer’s disease and innovative medicines for patients suffering from diseases of high unmet need.”
Detailed data from the ENGAGE and EMERGE studies will be presented at future medical meetings to inform ongoing research. ENGAGE and EMERGE are global Phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate the efficacy and safety of aducanumab. The primary objective of the study was to evaluate the efficacy of monthly doses of aducanumab as compared with placebo in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score. Secondary objectives were to assess the effect of monthly doses of aducanumab as compared to placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (ADAS-Cog 13), and AD Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL-MCI).
As part of this decision, the EVOLVE Phase 2 safety study and the long-term extension of the PRIME Phase1b study of aducanumab will also be discontinued. Initiation of the aducanumab Phase 3 secondary prevention trial will be assessed while the data from ENGAGE and EMERGE are further evaluated.
Aducanumab (BIIB037) is an investigational compound being studied for the treatment of early Alzheimer’s disease. Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. Aducanumab is a human monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called Reverse Translational Medicine (RTM). Since October 2017, Biogen and Eisai have collaborated on the development and commercialization of aducanumab globally. In addition, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of aducanumab, a process allowing priority reviews by the FDA for drugs deemed as having potential to treat serious conditions and tackle key unmet medical needs.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, MS and neuroimmunology, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
Leveraging the experience gained from the development and marketing of Aricept®, a treatment for Alzheimer's disease and dementia with Lewy bodies, Eisai has been working to establish a social environment that involves patients in each community in cooperation with various stakeholders including the government, healthcare professionals and care workers, and is estimated to have held over ten thousand dementia awareness events worldwide. As a pioneer in the field of dementia treatment, Eisai is striving to not only develop next generation treatments but also to develop diagnosis methods and provide solutions.
For more information about Eisai Co., Ltd., please visit www.eisai.com.
Biogen Safe Harbor
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the futility analysis for the Phase 3 studies of aducanumab, the identification and treatment of Alzheimer’s disease, the anticipated benefits and potential of Biogen’s collaboration arrangements with Eisai and the potential of Biogen’s commercial business and pipeline programs, including aducanumab. These statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “potential,” “will” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during our clinical trials; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen’s drug candidates, including aducanumab; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; uncertainty of success in the development and potential commercialization of aducanumab and/or other Biogen drug candidates; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise.
Eisai Co., Ltd.
Public Relations Department
Public Relations Department
Eisai Co., Ltd.
Investor Relations Department
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Fortuna CEO purchases company shares17.5.2019 21:00:00 CEST | Pressemelding
VANCOUVER, British Columbia, May 17, 2019 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that Jorge A. Ganoza, Chief Executive Officer of the Company, has increased his equity position in the Company by acquiring 170,000 common shares on the open market at an average price of US$2.59 per share. An insider report filing reflecting the share acquisition has been made on the SEDI website at www.sedi.ca. About Fortuna Silver Mines Inc. Fortuna is a growth oriented, precious metal producer with its primary assets being the Caylloma silver mine in southern Peru, the San Jose silver-gold mine in Mexico and the Lindero gold Project, currently under construction, in Argentina. The Company is selectively pursuing acquisition opportunities throughout the Americas and in select other areas. For more information, please visit its website at www.fortunasilver.com. ON BEHALF OF THE COMPANY Carlos Baca Investor Relations Manager Trading symbols: NYSE: FSM | TSX: FVI Inves
Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel17.5.2019 15:25:00 CEST | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 17, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it welcomes the updated Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019, published by the U.S. Centers for Disease Control and Prevention (CDC)1. These guidelines increase the focus on eradicating tuberculosis (TB) disease in the United States through an individual risk-based approach to screening and treatment for Healthcare Personnel (HCP). Key highlights from the updated guidelines include: Recommendation for TB Screening and Individual Based TB Risk Assessment on Hire : continue baseline screening of all HCPs upon hire with the addition of an individual risk assessment Recommendation to Focus Serial Testing on Higher Risk Individuals: decision to perform TB testing afte
First Dolby Cinema Opens in Germany with Kinopolis Gruppe in Munich17.5.2019 14:30:00 CEST | Pressemelding
MUNICH, Germany, May 17, 2019 (GLOBE NEWSWIRE) -- Dolby Laboratories, Inc. (NYSE:DLB) and Kinopolis Gruppe today announced the opening of the first Dolby Cinema in Germany at the renowned Mathäser Palast in Munich. Film fans can now enjoy the very best cinema presentation in the heart of the city, following the opening of the highly-anticipated site. Dolby Cinema combines Dolby Vision, Dolby Atmos, and bespoke design to create the perfect environment to be fully immersed in the storytelling of a film. Dolby Vision is presented through a dual 4K laser, High Dynamic Range (HDR) projector system, and boasts a spectacular, ultra vivid picture. Compared to standard screens, the Dolby Vision image is twice as bright, 500 times the contrast ratio, has blacker blacks, and an unsurpassed colour palette. Cutting-edge Dolby Atmos sound transports viewers into the scene, filling the cinema with a soundscape that flows all around and above the audience. Dolby works with each cinema location to crea
Four Progressive Leaders to Receive the 2019 YPO Global Innovation Awards 17.5.2019 08:00:00 CEST | Pressemelding
Thirst CEO Mina Guli, RaySearch Laboratories AB CEO Johan Löf, Malwarebytes CEO Marcin Kleczynski & Apeel CEO James Rogers honored NEW YORK, May 17, 2019 (GLOBE NEWSWIRE) -- YPO, the premier global leadership organization for more than 27,000 chief executives, today announced the winners of its prestigious Global Innovation Awards. Presented in conjunction with YPO Innovation Week, the Global Innovation Awards annually recognizes YPO members who are making an impact through transformation around the globe in four categories: Social Impact, Medical, Technology, and Manufacturing. “Our goal for the 2019 Global Innovation Award winners is to recognize YPO member companies that are creating scalable solutions which address challenges both at a local and/or global level,” said Mohamed Alkady, YPO Global Innovation Awards Chair. “Each of these winners represent their category with glaring leadership and, most importantly, a clear mission and vision. This extraordinary group have demonstrated
Dr. Deep Saini appointed as Dalhousie University’s 12th President16.5.2019 21:09:00 CEST | Pressemelding
Halifax, NS, May 16, 2019 (GLOBE NEWSWIRE) -- Dalhousie University’s Board of Governors announced today that Dr. Deep Saini has been appointed as the university’s 12th President and Vice-Chancellor. Dr. Saini, who is currently Vice-Chancellor and President of the University of Canberra in Australia, was the unanimous choice of the search committee. He is an accomplished leader who combines significant Canadian post-secondary experience with a global outlook; a distinguished scientist whose belief in the transformative power of education has defined his life’s journey; and a warm, genuine and inspiring individual ready to build on Dal’s 200 years of achievement and chart a course towards even greater success in our third century ahead. “I am honoured and humbled by the opportunity to serve as the 12th President and Vice-Chancellor of Dalhousie University,” says Dr. Saini. “The university’s singular commitment to its anchor role in the region’s economic and social development is fittingl
PureCircle and Merisant Renew Stevia Supply Agreement16.5.2019 18:00:00 CEST | Pressemelding
Leading Tabletop Sweetener Company Will Increase Its Purchases of Great-Tasting Ingredients From Top Global Stevia Supplier CHICAGO, May 16, 2019 (GLOBE NEWSWIRE) -- PureCircle (LSE: PURE), the world’s leading producer and innovator of stevia sweeteners, has entered into a new stevia supply agreement with Merisant, one of the world’s leading producers of low- and zero-calorie tabletop sweeteners for consumers. This new and expanded partnership will help to ensure Merisant’s long-term supply of the best-tasting stevia ingredients. Merisant has been a partner and customer of PureCircle for the last ten years. Merisant’s sweetener products are sold in more than 90 countries worldwide. This new agreement focuses on the supply to Merisant of PureCircle’s next generation stevia sweetener ingredients like Reb M. PureCircle announced last year that it significantly increased its capacity to supply Reb M to consumer product companies. PureCircle’s Reb M is a next generation zero-calorie sweeten